<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01209845</url>
  </required_header>
  <id_info>
    <org_study_id>0909005766</org_study_id>
    <nct_id>NCT01209845</nct_id>
  </id_info>
  <brief_title>Ketamine for Low Mood States in the ER</brief_title>
  <official_title>Low Dose Ketamine for Low Mood States: An Emergency Department Feasibility Study for Depressed Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hope to see if a commonly used drug such as ketamine could help depressed&#xD;
      ER patients feel better and improve their mood quickly.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rapid-onset antidepressants could have important clinical impact if their benefits extended&#xD;
      to Emergency Department (ED) patients. We hope to explore the preliminary feasibility,&#xD;
      tolerability and efficacy of single-dose, intravenous (IV) ketamine in depressed ED patients&#xD;
      who presented with suicide ideation (SI).&#xD;
&#xD;
      The manuscript (article) for this study has been retracted because Yale University conducted&#xD;
      an investigation that determined that the description of the research was not accurate. The&#xD;
      article misrepresents both the protocol-specified doses and the actual delivered doses of&#xD;
      ketamine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>40, 80, 120, 240 minutes after administration of drug</time_frame>
    <description>The MADRS measures mood (depression) and item 10 measures suicide ideation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>recruitment success and retention of subjects in the ER</measure>
    <time_frame>initial recruitment of eligible subjects in the ER and for two weeks after administration of drug</time_frame>
    <description>All patient subjects are admitted and we will follow them in the hospital and for 2 weeks after hospital discharge.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Depression</condition>
  <condition>Suicide Ideation</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were administered a single sub-anaesthetic i.v. bolus of ketamine (0.2 mg/kg over 1-2 min) in the ED, with continuous monitoring of vital signs, adverse events and psychotomimetic side-effects for 4 h post-administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketamine</intervention_name>
    <description>intravenous ketamine(0.2 mg/kg) over 1-2 minutes IV</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adults (&gt;18yrs) presenting to the Emergency department with symptoms of depression&#xD;
             and/or suicide ideation (MADRS&gt;30) with ability to give informed consent.&#xD;
&#xD;
          -  medically stable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  psychosis, bipolar, or other significant physical or mental illness&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  non-voluntary status&#xD;
&#xD;
          -  urine drug screen positive for drugs of abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory L Larkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University School of Medicine, Department of Emergency Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale New Haven Hospital Emergency Department</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Larkin GL, Beautrais AL. A Preliminary Naturalistic Study of Low-Dose Ketamine for Depression and Suicide Ideation in the Emergency Department. Int J Neuropsychopharmacol. 2017 Jul 1;20(7):611. doi: 10.1093/ijnp/pyx035.</citation>
    <PMID>28637184</PMID>
  </results_reference>
  <results_reference>
    <citation>Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011 Sep;14(8):1127-31. doi: 10.1017/S1461145711000629. Epub 2011 May 5. Retraction in: Int J Neuropsychopharmacol. 2017 Jul 1;20(7):611.</citation>
    <PMID>21557878</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 30, 2010</study_first_submitted>
  <study_first_submitted_qc>September 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2010</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>suicide ideation</keyword>
  <keyword>emergency department</keyword>
  <keyword>ketamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Suicide</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

